Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Physical Exercise, APOE E4 Genotype And Cognitive Trajectories: The Mayo Clinic Study Of Aging
Syrjanen, Jeremy A. , Vassilaki, Maria , Trautwein, Sandra , Barisch‐Fritz, Bettina , Boes, Klaus, Wöll, Alexander , Kremers, Walter K. , Petersen, Ronald C. , Kremers, Walter K , Krell‐Roesch, Janina , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S. , Geda, Yonas E.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 473-473

10.1249/01.mss.0000561924.66614.c4 Get It

Spontaneous radial artery pseudoaneurysm in an infant due to idiopathic medial hypoplasia – a case report
Kesler, William W. , Maleszewski, Joseph J. , Payatakes, Alexander

Mayo Clinic

Case Reports in Plastic Surgery and Hand Surgery | June 18, 2019 | Volume: 6 | Issue: 1 | Pages: 69-73

10.1080/23320885.2019.1614449 | PMID 31259203 Get It

Role of Doppler echocardiography for assessing right ventricular cardiac output in patients with atrial septal defect
Yogeswaran, Vidhushei , Kanade, Rahul , Mejía, Camilo A. , Fatola, Ayotola , Kothapalli, Srikanth, Najam, Maria , Angirekula, Mounika, Osma, Karim, Jessey, Mathews, Hagler, Donald J. , Egbe, Alexander C. , Mathew, Jessey , Osman, Karim T. , Mejia, Camilo, Sandhyavenu, Harigopal , Hagler, Donald, Egbe, Alexander C , Jessey, Mathews

Mayo Clinic

Congenital Heart Disease | June 17, 2019 | Volume: 14 | Issue: 5 | Pages: 713-719

10.1111/chd.12813 | PMID 31207173 Get It

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, Martin S. , Wang, Eunice S. , Altman, Jessica K. , Appelbaum, Frederick R. , Bixby, Dale L. , Coutré, Steven , Fathi, Amir T. , Fiorella, Melanie, Foran, James M. , Hall, Aric C. , Jacoby, Meagan A., LeBlanc, Thomas W. , Mannis, Gabriel N. , Marcucci, Guido , Martin, Michael G. , O’Donnell, Margaret, Olin, Rebecca L. , Peker, Deniz , Perl, Alexander E. , Pratz, Keith W. , Shami, Paul J. , Stone, Richard M. , Strickland, Stephen A. , Wieduwilt, Matthew J. , Gregory, Kristina M., OCN, Hammond, Lydia J., Ogba, Ndiya , Wang, Eunice S. , Strickland, Stephen Anthony , Leblanc, Thomas , Bhatt, Vijaya Raj , Lima, Marcos de , Lancet, Jeffrey E. , Mims, Alice S , Pollyea, Daniel Aaron , Prébet, Thomas , Ravandi, Farhad , OCN

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 721-749

10.6004/jnccn.2019.0028 | PMID 31200351 Get It

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
S865 CHANGE IN CLONE SIZE DOES NOT PREDICT RISK OF MAJOR ADVERSE VASCULAR EVENTS: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
Larratt, Loree, Go, RS, David, Daniel, Höchsmann, Britta , Gustovic, Philippe, Latour, Régis Peffault de , Kulasekararaj, Austin , Wilson, A., Kulagin, Alexander

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 387

10.1097/01.hs9.0000561740.44478.b8 Get It

Background:In paroxysmal nocturnal hemoglobinuria (PNH), the granulocyte clone size is often used as an indicator of disease severity. However, the prognostic value of changing clone size on clinical outcomes in PNH is not well understood.Aims:To assess the prognostic value of change in PNH granulocyte clone size on the risk of developing major adverse vascular events (MAVE) or high disease activity (HDA: elevated hemolysis [lactate dehydrogenase {LDH} ≥1.5 x upper limit of normal] and one or more PNH‐related symptom[s]) in patients with PNH.Methods:The International PNH Registry is the largest worldwide observational study of patients with a diagnosis of PNH or a detected PNH clone as low as 0.01%. This study assessed patients with a baseline value for PNH clone size (defined as the closest value to disease onset) and at least one additional clone size value, who were untreated with complement inhibitor therapy at enrollment, and had ≥12 months of untreated follow‐up. Patients were stratified by clone size at baseline and change in clone size was estimated using regression models of clone size vs duration from disease start, adjusted for baseline clone size. Patients were categorized as having stable, increasing, or decreasing clone size depending on the slope, where a change in clone size >10% per year was considered increasing/decreasing. Prognostic value of change in clone size was assessed using Poisson regression to estimate rate ratios of MAVE and logistic regression to estimate odds ratios of HDA during follow‐up, with stable clone size as the reference. Adjusted models included baseline LDH ratio category, history of bone marrow disease at baseline, baseline clone size, and duration.Results:As of April 3, 2018, a total of 1894 patients were available for analysis: cohort (COH) 1 (clone size >0.01% to ≤1%, n = 381); COH 2 (clone size >1% to ≤5%, n = 318); COH 3 (clone size >5% to ≤10%, n = 159); COH 4 (clone size >10% to ≤50%, n = 480); COH 5 (clone size >50% to ≤100%, n = 556). Median duration was 3.5 years. Clone size was stable in only 16.2% of patients, as compared with 45.3% increasing and 38.5% decreasing; stable clone size was primarily seen in patients with a clone size ≤1% at baseline (58% of patients in COH 1 with a stable clone), with less than 10% of patients with a stable clone in the other cohorts. Clone size change over time was highly prognostic of HDA; patients with increasing and decreasing clone size had an increased risk of HDA, compared to patients with stable clone size, although this may be due to patients with a stable clone largely in COH 1 with a low risk of HDA; after adjusting, we see no increased risk of HDA in patients with decreasing clone size, but the increased risk of HDA in patients with increasing clone size is maintained (Table). Due to limited data on covariates at baseline, only 156 patients were available for this adjusted analysis. There was no difference in the MAVE rate in patients with increasing or decreasing clone size as compared with those with a stable clone size. The lack of effect was maintained even after adjusting for covariates (Table).Summary/Conclusion:This is the first analysis of the prognostic value of PNH clone size changes on clinical outcomes over time in patients with PNH. Increasing clone size over time was predictive of patients experiencing HDA during their disease course. Interestingly, no difference in the MAVE rate was seen in patients with increasing or decreasing clone size, suggesting that change in clone size does not change the increased risk of MAVE in patients with PNH.image
Arabinose Alters Both Local and Distal H–D Exchange Rates in the Escherichia coli AraC Transcriptional Regulator
Tischer, Alexander , Brown, Matthew J. , Schleif, Robert , Auton, Matthew , Auton, Matthew , Tischer, Alexander , Brown, Matthew J.

Mayo Clinic

Biochemistry | June 14, 2019 | Volume: 58 | Issue: 26 | Pages: 2875-2882

10.1021/acs.biochem.9b00389 | PMID 31199144 Get It

Coronary Artery Disease in Adults With Coarctation of Aorta: Incidence, Risk Factors, and Outcomes
Egbe, Alexander C. , Rihal, Charanjit S. , Thomas, Alexa , Boler, Amber, Mehra, Nandini , Andersen, Kylie J. , Kothapalli, Srikanth, Taggart, Nathaniel W. , Connolly, Heidi M. , Andersen, Kylie, Taggart, Nathaniel W , Andersen, Kylie , Thomas, Alexa L , Rihal, Charanjit S.

Mayo Clinic

Journal of the American Heart Association | June 14, 2019 | Volume: 8 | Issue: 12 | Pages: No page available

10.1161/jaha.119.012056 | PMID 31195876 Get It

Background Premature coronary artery disease ( CAD ) is common in patients with coarctation of aorta ( COA ), but there are limited data about any direct relationship (or lack thereof) between COA and CAD . We hypothesized that atherosclerotic cardiovascular disease risk factors, rather than COA diagnosis, was the primary determinant of CAD occurrence in patients with COA . Methods and Results This is a retrospective study of 654 COA patients and a control group of 876 patients with valvular pulmonic stenosis and tetralogy of Fallot to determine prevalence and independent risk factors for CAD . There was no evidence of a difference in the unadjusted CAD prevalence between the COA and control groups (7.8% versus 6.3%, P =0.247), but premature CAD was more common in COA patients (4.4% versus 1.8%, P =0.002). In the analysis of a propensity‐matched cohort of 126 COA and 126 control patients, there was no evidence of a difference in overall CAD prevalence (6.3% versus 5.6% versus P =0.742) and premature CAD prevalence (4.8% versus 3.2%, P =0.518). The multivariable risk factors for CAD were hypertension (odds ratio [ OR ] 2.14; 95% CI 1.36–3.38), hyperlipidemia ( OR 3.33; 95% CI 2.02–5.47), diabetes mellitus ( OR 1.98; 95% CI 1.31–3.61), male sex ( OR 2.05; 95% CI 1.33–3.17), and older age per year ( OR 1.06; 95% CI 1.04–1.07). Conclusions After adjusting for atherosclerotic cardiovascular disease risk factors, we did not find evidence of a difference in CAD risk between the patients with COA and other patients with congenital heart disease.
Outcomes of Pregnancy in Patients With Prior Right Ventricular Outflow Interventions
Egbe, Alexander C. , El‐Harasis, Majd , Miranda, William R. , Ammash, Naser M., Rose, Carl H., Fatola, Ayotola , Kothapalli, Srikanth, Abdelsamid, Mohamed Farouk, Connolly, Heidi M.

Mayo Clinic

Journal of the American Heart Association | June 14, 2019 | Volume: 8 | Issue: 12 | Pages: No page available

10.1161/jaha.118.011730 | PMID 31195875 Get It

Background The purpose of this study was to compare the incidence of pregnancy‐related adverse outcomes ( PRAO ) between patients with versus without hemodynamically significant right ventricle outflow tract ( RVOT) . Methods and Results This was a retrospective cohort study of all pregnant patients with isolated RVOT lesions undergoing evaluation at the Mayo Clinic, 1990 to 2017. Hemodynamic significance was defined as ≥moderate pulmonary/conduit stenosis (≥3 m/s) and/or ≥moderate regurgitation. Patients with concomitant significant left heart disease were excluded. PRAO was defined as cardiovascular, obstetric, and/or neonatal complications occurring during the pregnancy through 6 weeks postpartum. A total of 224 pregnancies in 114 patients with RVOT lesions were identified; 38 pregnancies occurred in 24 patients with hemodynamically significant RVOT . Forty‐eight (21%) pregnancies ended in spontaneous abortion. Of the 173 completed pregnancies, median gestational age at delivery was 38 (35–40) weeks and median birth weight 2965 (2065–4122) g. Seven pregnancies (4%) were complicated by cardiovascular events, 14 (8%) by obstetric complications, with adverse neonatal outcomes occurring in 38 (22%). There were no maternal deaths. The incidence of spontaneous abortion and PRAO were similar in both the RVOT and hemodynamically significant RVOT groups. As an isolated condition, Tetralogy of Fallot–pulmonary atresia was associated with spontaneous abortion and neonatal complications. Conclusions The risk of cardiovascular complications was low in patients with isolated RVOT lesions, and hemodynamically significant RVOT lesions were not associated with either cardiovascular complications or PRAO . Further studies are required to explore the factors responsible for PRAO in patients with Tetralogy of Fallot–pulmonary atresia.
Abnormal Pulmonary Arterial Elastance Is Associated With Reduced Exercise Capacity in Tetralogy of Fallot
Egbe, Alexander C. , Anavekar, Nandan S., Connolly, Heidi M.

Mayo Clinic

Journal of the American Heart Association | June 11, 2019 | Volume: 8 | Issue: 12 | Pages: No page available

10.1161/jaha.118.011731 | PMID 31181980 Get It

Background A previous study reported histologic abnormalities in the pulmonary artery ( PA ) of patients with tetralogy of Fallot ( TOF ). However, the potential effect of these anatomical findings on PA vascular function has not been studied. We hypothesized that TOF patients had abnormal PA vascular function, and that PA vascular function was associated with exercise capacity. Methods and Results This a study of adult TOF patients who had cardiac magnetic resonance imaging and echocardiogram (on the same day) at Mayo Clinic, 2002–2015. In order to test the study hypothesis, we compared PA elastance index ( PAE i) between 207 TOF patients and a referent group of 8 subjects without structural heart disease. PAE i was calculated as a quotient of PA systolic pressure and cardiac magnetic resonance imaging–derived right ventricular stroke volume. Mean age was 33±13 and 36±4 years in the TOF and referent groups respectively. TOF patients had higher PAE i compared with the referent group (0.62±0.12 versus 0.48±0.08 mm Hg/ mL /m 2 ; P =0.001). There was a good correlation between PAE i and peak oxygen consumption (adjusted R 2 =0.73; r =0.85; P <0.001). After multivariate adjustment for potential confounders, PAE i was independently associated with peak oxygen consumption (adjusted R 2 =0.69; r =0.83; P <0.001). Conclusions The high PA elastance in the TOF group may be attributed to abnormal PA vascular function. The association between PAE i and exercise intolerance suggests that PA vascular dysfunction may contribute to exercise intolerance, which is an important clinical problem in this population. Further studies are required to validate our findings and explore potential therapies to improve PA vascular function in this population.
Barriers to accrual and enrollment in brain tumor trials
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Bent, Martin J. van den , Weller, Michael , Reardon, David A. , Wen, Patrick Y. , Galanis, Evanthia , Weller, Michael , van den Bent, Martin J , Groot, John de , Armstrong, Terri S. , Chang, Susan Marina , Alexander, Brian M. , Bates, Amanda, Lin, Nancy U. , Mehta, Minesh P. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | June 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noz104 | PMID 31175826 Get It

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.